中國(guó)-匈牙利腦科學(xué)“一帶一路”聯(lián)合實(shí)驗(yàn)室將在腦疾病和腦圖譜這一前沿研究領(lǐng)域進(jìn)行積極探索，研究腦疾病的分子和神經(jīng)元環(huán)路機(jī)制、開(kāi)發(fā)新的診斷和治療方去，繪制靈長(zhǎng)類(lèi)重要腦區(qū)介觀神經(jīng)聯(lián)接圖譜。
此合作將深化中匈兩國(guó)在腦科學(xué)基礎(chǔ)研究領(lǐng)域的戰(zhàn)略協(xié)同，加速前沿技術(shù)突破與臨床轉(zhuǎn)化進(jìn)程，鞏固雙方在神經(jīng)科學(xué)全球創(chuàng)新版圖中的領(lǐng)先地位，進(jìn)一步提高腦疾病的診斷精度與治療效果，為醫(yī)療產(chǎn)業(yè)注入新動(dòng)力，進(jìn)而全面提升人民的健康水平。
The Joint Laboratory?aims to advance collaborative research in brain mapping and brain diseases through three strategic research directions:
Mapping brain-wide cell types and subcellular interactome and synaptic functions.
Understanding higher order cognitive functions and dysfunctions requires the characterization of synaptic connections among neuronal populations. First, we will characterize diverse neuronal cell types in mouse, non-human primate (NHP), and human brain samples using single-cell transcriptomic, proteomic, genomic, and epigenomic technologies. We will investigate the developmental emergence, age dependence, and pathological variations of specific cell types and their associated networks. Next, we will perform a detailed subcellular molecular analysis of synapses among the identified cell types, with special emphasis on NHP and human brains. By combining state-of-the-art super-resolution light microscopy, volume electron microscopy, and subcellular spatial transcriptomics, we will quantitatively characterize the transcript of the pre- and postsynaptic cells and protein composition of synapses, as well as synaptic transmission and plasticity. These data are essential for understanding neuronal network function and dysfunction.?By comparing NHP and human data, we will further identify human-specific synaptic motifs.
Deciphering?molecular and synaptic mechanisms for brain diseases using organoids, human tissues and animal models. By leveraging patient-derived organoids, we will investigate disease-associated genetic and epigenetic alterations, synaptic dysfunction, and neural network abnormalities in a human-relevant context. Complementary analyses of postmortem brain tissues will provide insights into pathological signatures in clinical samples. Parallel studies in genetically engineered animal models will enable mechanistic validation and exploration of circuit-level deficits. The integration of these models will bridge molecular insights with functional phenotypes, facilitating the identification of novel therapeutic targets for neurodevelopmental and neurodegenerative diseases such as autism, schizophrenia, and Alzheimer’s disease.
Developing?molecular tools for brain mapping and therapeutic therapies for brain disorders. We will (1)?design and optimize novel biosensors, optogenetic actuators, and CRISPR-based systems to precisely monitor and manipulate neuronal activity in disease-relevant contexts. (2) develop methods to map synaptic heterogeneity by developing ultra-sensitive transcriptome and spatial transcriptome detection of single synapses in a cell-type specific manner. (3) develop an super-resolution light microscope to visualize the structural dynamic of synapses in disease-relevant contexts. The primary goal is to translate these molecular tools into therapeutic interventions—such as gene therapy and synaptic reprogramming—to restore neural function. By integrating basic neuroscience with translational medicine through interdisciplinary collaboration, these research lines will advance precise treatments for brain disorders while developing scalable technologies for next-generation diagnostics and therapeutics.
